Clinical trials: Parkinsonian Disorders
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa
To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled-release levodopa/carbidopa 100/25 mg…
- Trial name
- NCT02169453
- Testing
- BIA 9-1067, Sinemet® CR 100/25
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)
This study will be an open-label, randomized, multi-center, 2-way crossover Pharmacokinetic PK evaluation of a single inhaled dose of CVT-301 84 mg and a single oral dose of carbidopa/levodopa CD/LD 25 mg/100 mg (Sinemet®) under…
- Trial name
- NCT03887884
- Testing
- CVT-301, Sinemet
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Acorda Therapeutics
Parkinson's Disease
A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JX2105 in Healthy Chinese Subjects
The purpose of the study is to evaluate the safety, tolerability after administration of single dose or multiple doses, and the pharmacokinetics (PK) of single and multiple doses of JX2105 in healthy study participants.
- Trial name
- NCT06537050
- Testing
- JX2105
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Zhejiang Jingxin Pharmaceutical Co., Ltd.
Idiopathic Parkinson's Disease
Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes
The purpose of this study is to determine the safety, efficacy and pharmacokinetics following administration of CVT-301 in treatment of "off" episodes in Parkinson's Disease patients.
- Trial name
- NCT01617135
- Testing
- CVT-301, Sinemet (carbidopa/levodopa)
- Where
- 7 sites in Israel, Serbia and 1 more
- Volunteers
- 25 people
- Sponsor
- Acorda Therapeutics
Parkinson Disease
A Study to Evaluate the Safety and Efficacy of ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features
The objective of this study is to test the efficacy and safety of unilateral subthalamotomy performed using the ExAblate System for the treatment of Parkinson's disease (PD) motor features.
- Trial name
- NCT03454425
- Testing
- Exablate Subthalamotomy
- Where
- Spain
- Volunteers
- 36 people
- Sponsor
- InSightec
Parkinson's Disease
Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study
The purpose of the study is to evaluate the effectiveness of the Medtronic Adaptive DBS therapy (aDBS) for Parkinson's Disease in China with the Percept family of Implantable Neurostimulators (Percept PC and Percept RC).
- Trial name
- NCT07216976
- Testing
- Percept™ PC and Percept RC with Adaptive DBS (aDBS™)
- Where
- 5 sites in China
- Volunteers
- 61 people
- Sponsor
- MedtronicNeuro
Parkinson Disease
WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects
The Phase 1 PK study is planned to evaluate the food effect on WD-1603 pharmacokinetics
- Trial name
- NCT04513340
- Testing
- WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS
- Where
- India
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Hong Kong WD Pharmaceutical Co., Limited
Movement Disorders (Incl Parkinsonism)
Correlation of Motor Metrics and Neurological Data
This is a pilot study to collect data with the Ceraxis product and standard movement disorders tests in order to prove and codify potential correlations.
- Trial name
- COMMAND (NCT05462080)
- Testing
- Ceraxis product
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Ceraxis Health, Inc
Parkinson Disease
Kinetic Tremor in Parkinsons Disease: Its Course Under Pramipexole (Mirapexin®) Treatment and Impact on Quality of Life
The study will compare the effect of pramipexole on different types of tremor and particularly kinetic tremor in early and advanced Parkinson's disease patients and will evaluate the course of tremor measured with spiralometry…
- Trial name
- NCT01100073
- Where
- 215 sites in Estonia, Latvia and 6 more
- Volunteers
- 1,703 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease
ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease
This is a feasibility study to evaluate the safety and initial effectiveness of unilateral ExAblate thermal ablation of the Vim thalamic nucleus of subjects suffering from medication-refractory, idiopathic, tremor-dominant PD…
- Trial name
- NCT01772693
- Testing
- ExAblate Transcranial MRgFUS
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- InSightec
Multiple System Atrophy
Study of ATH434 in Participants with Multiple System Atrophy
This study will assess the safety and efficacy of ATH434 in participants with Multiple System Atrophy
- Trial name
- NCT05109091
- Testing
- ATH434 dose level 1, ATH434 dose level 2
- Where
- 23 sites in United States, Australia and 4 more
- Volunteers
- 77 people
- Sponsor
- Alterity Therapeutics
Parkinson Disease
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
This study will be evaluating the safety and efficacy of insulin and glutathione in subjects with Parkinson's Disease compared to placebo.
- Trial name
- NOSE-PD (NCT05266417)
- Testing
- INS-GSH
- Where
- 4 sites in United States
- Volunteers
- 56 people
- Sponsor
- Gateway Institute for Brain Research
Idiopathic Parkinson Disease
Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias
This is a 41-week trial composed of two consecutive parts (Part A, 14 weeks and optional Part B, 27 weeks) to evaluate the efficacy of levetiracetam in controlling levodopa induced dyskinesias in adults with Idiopathic…
- Trial name
- NCT00160576
- Testing
- Levetiracetam
- Volunteers
- 30 people
- Sponsor
- UCB Pharma
Parkinson Disease
Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease
Study to measure the continued effectiveness of apomorphine after previous exposure of at least three months duration.
- Trial name
- NCT00200525
- Testing
- apomorphine HCl injection
- Volunteers
- 60 people
- Sponsor
- Mylan Bertek Pharmaceuticals
Parkinson Disease
Development of Digital Diagnostic Devices for Parkinson's Disease
In this project, ocular motor, pupil and gait data in people with Parkinson's disease (PD) will be collected in order to develop machine learning models for the diagnosis and monitoring of PD.
- Trial name
- NCT06663826
- Testing
- oculomotor and pupillary function assessment
- Where
- Switzerland
- Volunteers
- 116 people
- Sponsor
- machineMD AG
Parkinson's Disease
Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease
This is a multicenter, randomized, double-blind, placebo-controlled study of multiple ascending iv doses of MEDI341 in male and female subjects with Parkinson's Disease.
- Trial name
- NCT04449484
- Testing
- MEDI1341
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- AstraZeneca
Essential Tremor, Parkinson's Disease
Evaluation of the Infinity Deep Brain Stimulation Electrode Screening Mode Tool
The objective of this clinical investigation is to characterize the clinical performance of Abbott's Clinician Programmer Electrode Screening Mode tool (InformityTM tool) in programming InfinityTM deep brain stimulation (DBS)…
- Trial name
- EVIDENT (NCT03794661)
- Testing
- Clinician programmer electrode screening mode tool
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Abbott Medical Devices
Parkinson's Disease
A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa
The purpose of this study is to achieve approval for the use of carbidopa/levodopa/entacapone in early Parkinson's disease (PD) by demonstrating that when used as initial levodopa therapy in early PD…
- Trial name
- NCT00134966
- Testing
- capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)
- Where
- 60 sites in United States, Canada and 6 more
- Volunteers
- 493 people
- Sponsor
- Novartis
Parkinson Disease
A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
In this study, researchers will learn more about a study drug called BIIB122 in participants with early-stage Parkinson's disease (PD). The study will focus on participants with a specific genetic variant in their LRRK2 gene.
- Trial name
- LIGHTHOUSE (NCT05418673)
- Testing
- BIIB122
- Where
- 27 sites in United States, France and 4 more
- Volunteers
- 7 people
- Sponsor
- Biogen
Parkinson Disease, Genetic Predisposition
Study of the Genome, Gut Metagenome and Diet of Patients With Incident Parkinson's Disease
A case-control study to identify microbiome and genetic differences between healthy subjects and patients with incident Parkinson's disease.
- Trial name
- NCT04119596
- Testing
- 16S rRNA gene sequencing, DNA-microarray genotyping
- Where
- Russia
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Atlas Biomed
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.